# Immunodominance

Source: https://onco.cc/terms/immunodominance/  
OnCo record `immunodominance` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Immune responses to a set of possible targets are often uneven. Some epitopes attract a stronger measured response than others in the same setting.

## Summary

A primary mouse experiment showed that T-cell populations could compete for access to antigen-bearing presenting cells, changing responses to dominant and subdominant epitopes. That identifies one mechanism of immunodominance in the studied system. It does not supply a universal ranking of human tumor epitopes. The antigen design, presentation context and responding repertoire all need to remain attached to an observation of a dominant response.

## Fields

- Kind: Term
- Last checked: 2026-11-09

## Notes

- Immunodominance is a contextual hierarchy of measured responses, distinct from encoded target count and from epitope spreading. Presentation, precursor frequency, repertoire, priming, HLA, delivery, immune history, tissue and time can change the hierarchy. A favourable binding prediction does not establish immunogenicity, and more encoded targets do not guarantee balanced immunity or independent tumour coverage.
- Naive precursor frequency is the starting abundance of cells with a relevant specificity. Mouse LCMV and human HLA-A2-restricted HCV experiments linked precursor frequencies to response hierarchies. Binding alone did not strictly predict the hierarchy. These studies provide no universal cancer-vaccine weights, human marker requirement or instruction to remove dominant clones.
- Fictional matched IFN-gamma ELISpot means of 45, 11 and 5 spots for A, B and C, minus matched background 5, give 40, 6 and 0 spots per 200,000 plated PBMCs. A dominates that measured response. Protocol replicate and positivity rules classify C as undetectable. Zero adjusted spots do not prove absent tumour display or universal uselessness, nor do three encoded sequences imply three equally effective responses.
- A measured hierarchy needs offered targets, compartment, cell denominator, baseline, timing, matched per-target stimulation, background and positive controls. Detection thresholds and in vitro expansion can alter apparent ranking. Peptide response is not evidence of natural tumour display or tumour-cell killing.

## Sources

- T cells compete for access to antigen-bearing antigen-presenting cells.: https://doi.org/10.1084/jem.192.8.1105
- Kotturi et al., Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance (J Immunol 2008): https://pubmed.ncbi.nlm.nih.gov/18641351/
- Schmidt et al., Immunodominance of HLA-A2-restricted hepatitis C virus-specific CD8+ T cell responses is linked to naive-precursor frequency (J Virol 2011): https://pubmed.ncbi.nlm.nih.gov/21367907/
- Wells et al., Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction (Cell 2020): https://pubmed.ncbi.nlm.nih.gov/33038342/

## Connected records

- terms: [Epitope](https://onco.cc/terms/epitope/), [Epitope spreading](https://onco.cc/terms/epitope-spreading/), [Immune measurements and product evidence](https://onco.cc/terms/immune-product-evidence/), [Multi-epitope constructs and antigen processing](https://onco.cc/terms/multi-epitope-constructs/), [T-cell receptor repertoire diversity and clonality](https://onco.cc/terms/tcr-repertoire-clonality/)

---
JSON: https://onco.cc/api/v1/entities/immunodominance.json